Immunome merges with Morphimmune; Siegall new CEO; $125M PIPE at $5.75/share

Immunome Inc.

Morphimmune stockholders to own ~45% of combined company; Immunome stockholders ~55% on fully diluted basis.
Clay Siegall to become Chairman and CEO; board to include 2 from Morphimmune, 1 from Immunome, 4 independents.
PIPE financing of ~$125M at $5.75/share (or $5.91 for affiliates) from Enavate, EcoR1, Redmile.
Siegall employment agreement: $650K base, 50% bonus target, option for 2.14M shares at $5.91.
Closing conditions include S-4 effectiveness, Nasdaq listing, PIPE proceeds of $125M.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Immunome Inc. entered into Agreement and Plan of Merger and Reorganization with Morphimmune Inc. (effective 2023-06-29).

Action: entry
Agreement: merger
Counterparty: Morphimmune Inc.
Effective: 2023-06-29

Exact text from the filing

On June 29, 2023, Immunome, Inc., a Delaware corporation (“Immunome”), entered into an Agreement and Plan of Merger and Reorganization (the “Merger Agreement”) with Morphimmune Inc., a Delaware corporation (“Morphimmune”), a biotechnology company focused on developing targeted oncology therapeutics, and Ibiza Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Immunome (“Merger Sub”).

View on SEC.gov

Browse all material agreements →

Immunome Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-076136

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.